Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: You gotta ask yourself

Based on the current status where TPL gets 95% of the revenue from a $7M licensing quarter, what is their incentive to bring a speedy conclusion to the T3 situation?! Every move seems to push the court calendar out, and PTSC continues to burn money. Is TPL handling this court case in a fashion that is BEST for the MMP and PTSC, or simply what is best for TPL? Hard to know, but every court filing that seems to extend the time frame and obscure the facts from the public realm, IMO, (and especially in context with the disposition of the MMP licensing revneues) is suspect to gamesmanship of TPL against PTSC as much as it is to succeeding against the T3.

14
May 05, 2011 12:58PM
Share
New Message
Please login to post a reply